Gabapentin Tablet
Product Images NDC 68462-127

10 FDA label images from Glenmark Pharmaceuticals Inc., Usa · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68462-127). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation (Equation)

Equation (Equation)
A text panel showing a formula to calculate creatinine clearance (CLCr), using age, weight, serum creatinine, and a factor for female patients. The formula is relevant for dosing considerations in drug administration.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of Gabapentin showing a cyclohexane ring with an amino group (H2N) and a carboxylic acid (COOH) functional group attached to the ring.*
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, showing pain scores on the vertical axis and time in weeks on the horizontal axis.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
A line graph depicting mean pain score over 7 weeks comparing Placebo and Gabapentin at daily doses of 1800 mg and 2400 mg. The x-axis represents time in weeks with baseline, dose titration, and fixed dose periods labeled. The y-axis shows mean pain scores from 0 to 10. Gabapentin groups show decreasing pain scores compared to placebo.*
FDA Label Image

Figure3 (Figure3)

Figure3 (Figure3)
A bar chart showing the proportion of responders with at least 50% reduction in pain score at endpoint in two controlled postherpetic neuralgia (PHN) studies. Study 1 compares placebo (PBO) at 12% and Gabapentin (GBP) 3600 mg at 29%. Study 2 compares placebo (PBO) at 14%, GBP 1800 mg at 32%, and GBP 2400 mg at 34%. Significance levels are indicated with p-values <0.01 and <0.001.*
FDA Label Image

Figure4 (Figure4)

Figure4 (Figure4)
A scatter plot showing percentage difference versus daily dose (mg) for Gabapentin across three studies labeled a, b, and c. The x-axis represents daily doses from 600 to 1800 mg, and the y-axis shows percentage differences ranging approximately from 2% to 22%. Data points for each study are plotted with distinct square markers and labeled with letters a, b, and c.*
FDA Label Image

Glenmarklogo1 (Glenmarklogo1)

FDA Label Image

Glenmarklogo2 (Glenmarklogo2)

FDA Label Image

Label600mg (Label600mg)

Label600mg (Label600mg)
Gabapentin Tablets, USP 600 mg oral tablets packaging label from Glenmark Pharmaceuticals Inc., USA. The label states the strength as 600 mg, includes directions for pharmacists to dispense the Medication Guide separately, and shows a package count of 100 tablets. Storage and dosage information is partially visible on the right.*
FDA Label Image

Label800mg (Label800mg)

Label800mg (Label800mg)
Gabapentin Tablets, USP 800 mg oral tablets by Glenmark Pharmaceuticals Inc., USA. The package contains 100 tablets and displays the NDC 68462-127-01. It includes medication guide instructions for pharmacists and storage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.